Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Condition(s):Advanced or Refractory Leukemia, Lymphoma, Multiple MyelomaLast Updated:January 22, 2020Terminated
Hide Studies Not Open or Pending
Condition(s):Advanced or Refractory Leukemia, Lymphoma, Multiple MyelomaLast Updated:January 22, 2020Terminated
Condition(s):Multiple MyelomaLast Updated:November 6, 2020Completed
Condition(s):Acute Myeloid Leukemia; Multiple Myeloma; Diffuse Large B-cell LymphomaLast Updated:February 28, 2020Completed
Condition(s):Acute Myeloid Leukemia; Lymphoma; Multiple MyelomaLast Updated:September 24, 2021Not yet recruiting
Condition(s):Multiple MyelomaLast Updated:April 2, 2021Completed
Condition(s):Multiple MyelomaLast Updated:January 15, 2015Completed
Condition(s):Hematological Malignancies; Multiple Myeloma; Hodgkin’s Lymphoma; Cutaneous T Cell LymphomaLast Updated:September 21, 2023Active, not recruiting
Condition(s):Breast Adenocarcinoma; DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; Metastatic Malignant Neoplasm to the Bone; Pain; Musculoskeletal Complication; Urinary ComplicationsLast Updated:November 7, 2018Completed
Condition(s):Multiple MyelomaLast Updated:May 16, 2013Completed
Condition(s):Multiple MyelomaLast Updated:July 5, 2010Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.